AEON Biopharma (AEON) via Priveterra Acq (PMGM) deck
AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets.
%20via%20Priveterra%20Acq%20(PMGM)%20deck){kind=link}